Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study-Reference-Cited by-同舟云学术

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Published:2023-03 Issue: Volume:57 Page:101826
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Sofen Howard^ORCID,Bissonnette Robert,Yosipovitch Gil,Silverberg Jonathan I.,Tyring Stephen,Loo Wei Jing,Zook Matthew,Lee Mark,Zou Liangxing,Jiang Guang-Liang,Paolini John F.

Funder

Kiniksa Pharmaceuticals

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Chronic prurigo of nodular type: a review;Zeidler;Acta Derm Venereol,2018

2. Diagnostic workup and evaluation of patients with prurigo nodularis;Kwon;Medicines (Basel, Switzerland),2019

3. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis;Williams;Expert Rev Clin Pharmacol,2021

4. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus;Elmariah;J Am Acad Dermatol,2021

5. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European academy of dermatology and venereology network on assessment of severity and burden of pruritus (PruNet) cross-sectional trial;Steinke;J Am Acad Dermatol,2018

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

2. Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis;PLOS ONE;2024-08-26

3. Emerging Therapeutics in Chronic Urticaria;Immunology and Allergy Clinics of North America;2024-08

4. Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation;Journal of Investigative Dermatology;2024-08

5. Novel therapeutic receptor agonists and antagonists in allergic conjunctivitis;Current Opinion in Allergy & Clinical Immunology;2024-07-22